Spotlight On... Incyte shares slip as PhII flop signals new problems ahead; Manchin says he'd filibuster Califf's nomination to head FDA; FDA approves Takeda's GERD drug; Human Longevity buys LifebankUSA; and more...

Incyte ($INCY) took a nasty hit on its share price today after it reported that a combo study of Jakafi (ruxolitinib) and regorafinib (Bayer's Stivarga) failed a Phase II study on colorectal cancer. An interim analysis of the data concluded that the trial was a flop and analysts concluded that the risk of failure for pancreatic cancer, as well solid tumors in general, has gone up considerably. Incyte's shares dropped about 10% on the news. Not all analysts are so bearish, but in today's bear market for biotech stocks bad news is heavily amplified. Release

@FierceBiotech: UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Turn out the lights, the party is over: Gov't finds Theranos lab poses 'immediate jeopardy to patient safety.' CNBC article | Follow @JohnCFierce

> Robert Califf is facing growing opposition to his nomination as the new head of the FDA. West Virginia Senator Joe Manchin said he would filibuster the nomination, joining a group of lawmakers who have attacked Califf for his past ties with the pharma industry. Story

> The FDA has approved Takeda's Dexilant SoluTab delayed-release orally disintegrating tablets, a new formulation of dexlansoprazole used to treat GERD. Release

> The genomics company Human Longevity has struck a deal to acquire LifebankUSA, which is involved in placental and cord blood banking. Release

Medical Device News

@FierceMedDev: Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. Article | Follow @VarunSaxena2

@EmilyWFierce: Dog flu sweeps the U.S. with two more confirmed cases in Washington state. FierceAnimalHealth story | Follow @EmilyWFierce

> Investor urges J&J to spin out poor-performing device, consumer businesses. Report

> HeartWare succumbs to activist investors, calls off planned Valtech purchase. Story

> CMS draws blood, says Theranos poses 'immediate jeopardy to patient health.' Article

Pharma News

@FiercePharma: No obvious China baby bump for J&J as one-child policy ends. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: Novartis is revamping its manufacturing after having disposed of 25 plants. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI: U.K. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis. Article | Follow @CarlyHFierce

> Riding Q4 diabetes growth, Lilly aims for even more with Jardiance. Report

> State AG's protest against Gilead pricing destined to fail, legal observers suggest. Story

> Big investor pushes 'underperforming' J&J to step up or split up. Article

CRO News

> PRA recruits a U.K. marketing firm to help it reach more patients. Report

> In the midst of cuts, Parexel signs new research deal. More

> Parexel dims its revenue expectations despite a solid quarter. Story

> Icon launches new tech with promise to simplify adaptive trials. News

> BioClinica notches up another deal, this time with EPS. Article

Pharma Manufacturing News

> Lilly closing two animal health manufacturing plants picked up from Novatis. Article

> Baxter recalls saline, other products, contaminated by cardboard, cloth and skin. News

> Novartis revamping manufacturing after hiving off 25 plants. More

> GSK production coming up short for meningitis B vax, causing some shortages. Item

> Recipharm wrapping up its $105M deal for Indian sterile injectables maker Nitin. Article

Pharma Asia News

> India's Supreme Court allows Cipla move in Roche patent case. News

> Sino Biopharma's asset management deal drawing negative reviews. Report

> 3SBio buys a larger stake in CP Guojian Pharma for $150M. Story

> Novartis expects India's Sun to meet February U.S. generic Gleevec launch. More

> Another legal test for U.S. in case of Chinese scientists accused of stealing GSK secrets. Article

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.